Genital Warts



Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response


Condition:   Genital Warts
Interventions:   Biological: Vaccination with Gardasil;   Biological: Injection of Normal Saline
Sponsor:   Assistance Publique - Hôpitaux de Paris
Not yet recruiting


Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions


Conditions:   Anogenital Human Papillomavirus Infection;   Condyloma Anal
Interventions:   Drug: Imiquimod 5% cream;   Drug: Placebo cream;   Procedure: Fulguration
Sponsor:   Medical University Innsbruck
Not yet recruiting


A Trial of a New Botanical Drug For the Treatment of External Condylomata Acuminata in Adult Subjects


Condition:   Condylomata Acuminata
Intervention:   Drug: VIR007
Sponsor:   ViroXis Corporation
Not yet recruiting


Safety and Efficacy of Immune Therapy for Condyloma


Condition:   Condylomata Acuminata
Intervention:   Biological: DC-CIK immunotherapy
Sponsor:   Shenzhen Second People's Hospital
Recruiting


Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients


Condition:   Genital Wart
Interventions:   Biological: tuberculin;   Device: cryotherapy
Sponsor:   Assiut University
Not yet recruiting


Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis


Condition:   Anal Condyloma
Intervention:   Procedure: acetic acid test
Sponsor:   Hospices Civils de Lyon
Recruiting


Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients


Condition:   Anogenital Dysplasia
Intervention:  
Sponsors:   Bispebjerg Hospital;   Danish Cancer Society
Recruiting


Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts


Condition:   Condylomata Acuminata (External)
Interventions:   Drug: Omiganan (CLS001) topical gel;   Drug: Vehicle topical gel
Sponsors:   Cutanea Life Sciences, Inc.;   Leiden University Medical Center
Completed


A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients


Condition:   Condyloma
Interventions:   Drug: AP611074 5% gel;   Drug: AP611074 matching placebo
Sponsor:   Anaconda Pharma
Recruiting


Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)


Conditions:   Condylomata Acuminata;   Papillomavirus Infections;   Sexually Transmitted Diseases
Interventions:   Drug: Ranpirnase;   Drug: Vehicle
Sponsor:   Tamir Biotechnology, Inc.
Completed


Efficacy and Tolerability of Topical LFX453 for External Genital Warts


Condition:   External Genital Warts
Interventions:   Drug: Investigational Treatment;   Drug: Aldara
Sponsor:   Novartis Pharmaceuticals
Completed


Topical NVN1000 for the Treatment of External Genital and Perianal Warts


Conditions:   Genital Warts;   Perianal Warts
Interventions:   Drug: NVN1000;   Other: Vehicle Gel
Sponsors:   Novan, Inc.;   PPD
Active, not recruiting


Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts


Condition:   Anogenital Warts
Intervention:   Drug: Picato
Sponsor:   LEO Pharma
Completed


Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment


Condition:   External Genital Warts
Interventions:   Drug: Sinecatechins 15% Ointment;   Drug: Cryotherapy alone
Sponsors:   Icahn School of Medicine at Mount Sinai;   Fougera Pharmaceuticals Inc.
Completed


A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts


Conditions:   Anogenital Warts;   Condylomata Acuminata
Interventions:   Drug: Topical NO;   Drug: Placebo
Sponsors:   University of Aberdeen;   Prostrakan Pharmaceuticals;   Erasmus Medical Center
Completed


Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts


Condition:   External Genital Warts
Interventions:   Drug: 15% AS101 gel;   Drug: Vehicle
Sponsor:   BioMAS Ltd
Recruiting


Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)


Conditions:   Condyloma Acuminata;   Genital Warts;   Condylomata Acuminata;   Venereal Warts
Interventions:   Drug: Vehicle gel;   Drug: SR-T100 gel with 1.0 % SM;   Drug: SR-T100 gel with 2.3% SM
Sponsor:   G&E Herbal Biotechnology Co., LTD
Active, not recruiting


Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)


Conditions:   Genital Warts;   Anal Cancer;   Anal Intraepithelial Neoplasia
Intervention:   Biological: 9vHPV Vaccine
Sponsor:   Merck Sharp & Dohme Corp.
Completed


A RTC to Examine the Effectiveness of 400 mg of Oral Zinc Gluconate as Adjunctive Therapy for Ano-genital Warts


Conditions:   Genital Warts;   HPV
Interventions:   Drug: Oral Zinc;   Drug: Placebo
Sponsors:   University of British Columbia;   British Columbia Centre for Disease Control
Terminated


A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006)


Conditions:   Cervical Cancers;   Vulvar Cancers;   Vaginal Cancers;   Genital Warts
Interventions:   Biological: V503;   Biological: Placebo to V503
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Human Papillomavirus (HPV) Genotypes in Genital Warts in Colombian Population


Conditions:   Genital Warts;   HPV Infections
Intervention:   Procedure: Biopsy Excisional
Sponsor:   La Fundacion para la Investigacion y el Desarrollo
Completed


Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)


Conditions:   Cervical Cancer;   Genital Warts
Interventions:   Biological: V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years;   Biological: Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)


Conditions:   Cervical Cancer;   Genital Warts
Interventions:   Biological: Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine;   Biological: Matching Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)


Conditions:   Cervical Cancer;   Genital Warts
Intervention:   Biological: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years
Sponsor:   Merck Sharp & Dohme Corp.
Completed


An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)


Condition:   Condylomata Acuminata
Interventions:   Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Refine Your Search Advanced Search